Benign Prostatic Hyperplasia – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Benign Prostatic Hyperplasia – Pipeline Review, H2 2017’, provides an overview of the Benign Prostatic Hyperplasia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia

The report reviews pipeline therapeutics for Benign Prostatic Hyperplasia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Benign Prostatic Hyperplasia therapeutics and enlists all their major and minor projects

The report assesses Benign Prostatic Hyperplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

AndroScience Corp

Aphios Corp

Astellas Pharma Inc

BCWorld Pharm Co Ltd

Biolab Farmaceutica Ltda

Chong Kun Dang Pharmaceutical Corp

Curadis GmbH

Dongkook Pharmaceutical Co Ltd

GL Pharm Tech Corp

Health Ever Bio-Tech Co Ltd

Jeil Pharmaceutical Co Ltd

MEI Pharma Inc

Meiji Seika Pharma Co Ltd

Mezzion Pharma Co Ltd

Nymox Pharmaceutical Corp

Ono Pharmaceutical Co Ltd

OPKO Health Inc

SK Chemicals Co Ltd

Sophiris Bio Inc

Sun Pharma Advanced Research Company Ltd

The Female Health Company

XuanZhu Pharma Co Ltd

Yungjin Pharm Co Ltd

Yuyu Pharma Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Benign Prostatic Hyperplasia - Overview 9

Benign Prostatic Hyperplasia - Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 17

Benign Prostatic Hyperplasia - Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development 26

Addex Therapeutics Ltd 26

AndroScience Corp 26

Aphios Corp 26

Astellas Pharma Inc 27

BCWorld Pharm Co Ltd 27

Biolab Farmaceutica Ltda 28

Chong Kun Dang Pharmaceutical Corp 28

Curadis GmbH 29

Dongkook Pharmaceutical Co Ltd 29

GL Pharm Tech Corp 30

Health Ever Bio-Tech Co Ltd 30

Jeil Pharmaceutical Co Ltd 30

MEI Pharma Inc 31

Meiji Seika Pharma Co Ltd 31

Mezzion Pharma Co Ltd 32

Nymox Pharmaceutical Corp 32

Ono Pharmaceutical Co Ltd 32

OPKO Health Inc 33

SK Chemicals Co Ltd 33

Sophiris Bio Inc 34

Sun Pharma Advanced Research Company Ltd 34

The Female Health Company 35

XuanZhu Pharma Co Ltd 35

Yungjin Pharm Co Ltd 36

Yuyu Pharma Inc 36

Benign Prostatic Hyperplasia - Drug Profiles 38

(alfuzosin hydrochloride ER + tadalafil) - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

(dutasteride + tadalafil) - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

(solifenacin + tamsulosin) - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

(tadalafil + tamsulosin hydrochloride) - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

ADX-68692 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ASC-JM.X2 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

AUS-131 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

BCWPE-004 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

BL-214 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

CR-1447 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

fexapotide triflutate - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

KKM-1202 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

L-1AD3 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

MCS-2 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

NCE-403 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

ONO-8430506 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

S-0131632 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

sirolimus - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Sperol - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

talaporfin sodium - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

tamsulosin hydrochloride - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

tamsulosin hydrochloride CR - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

tamsulosin hydrochloride DR - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

tamsulosin SR - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

tertomotide - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

topsalysin - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

TT-701 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

udenafil - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

XZP-5849 - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

YBH-1603 - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

YOB-1604 - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

YY-201 - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

Benign Prostatic Hyperplasia - Dormant Projects 98

Benign Prostatic Hyperplasia - Discontinued Products 101

Benign Prostatic Hyperplasia - Product Development Milestones 102

Featured News & Press Releases 102

Nov 07, 2017: Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana 102

Oct 13, 2017: Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah 103

Oct 10, 2017: Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12 103

Sep 25, 2017: Nymox Announces October 12 Symposium for Company's BPH Drug at American Urological Association Meeting 104

Sep 15, 2017: Mayne Pharma Adds Urorec (silodosin) Capsules to Its Australian Portfolio 104

Sep 14, 2017: Nymox Announces New Symposium for Companys BPH Drug at American Urological Association Meeting October 5 105

Sep 14, 2017: Nymox Announces Validation by the European Member States of European Marketing Authorization Application for Fexapotide Triflutate for Benign Prostatic Hyperplasia 105

Aug 07, 2017: Nymox Announces Symposium for Company's BPH Drug at American Urological Association Meeting in September 106

May 31, 2017: Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials 106

May 08, 2017: NYMOX Files For Approval of First In Class Prostate Drug in Europe 108

May 03, 2017: NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe 108

Mar 29, 2017: Nymox Provides Update on Fexapotide Development 109

Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical’s Internally Developed Innovative Patented New Drug - Fadanafil 109

Nov 29, 2016: Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy 109

Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68692 111

Appendix 112

Methodology 112

Coverage 112

Secondary Research 112

Primary Research 112

Expert Panel Validation 112

Contact Us 112

Disclaimer 113

List of Tables

List of Tables

Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017 10

Number of Products under Development by Companies, H2 2017 12

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13

Number of Products under Development by Universities/Institutes, H2 2017 14

Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16

Products under Development by Universities/Institutes, H2 2017 17

Number of Products by Stage and Target, H2 2017 19

Number of Products by Stage and Mechanism of Action, H2 2017 21

Number of Products by Stage and Route of Administration, H2 2017 23

Number of Products by Stage and Molecule Type, H2 2017 25

Benign Prostatic Hyperplasia – Pipeline by Addex Therapeutics Ltd, H2 2017 26

Benign Prostatic Hyperplasia – Pipeline by AndroScience Corp, H2 2017 26

Benign Prostatic Hyperplasia – Pipeline by Aphios Corp, H2 2017 27

Benign Prostatic Hyperplasia – Pipeline by Astellas Pharma Inc, H2 2017 27

Benign Prostatic Hyperplasia – Pipeline by BCWorld Pharm Co Ltd, H2 2017 28

Benign Prostatic Hyperplasia – Pipeline by Biolab Farmaceutica Ltda, H2 2017 28

Benign Prostatic Hyperplasia – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 29

Benign Prostatic Hyperplasia – Pipeline by Curadis GmbH, H2 2017 29

Benign Prostatic Hyperplasia – Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2017 29

Benign Prostatic Hyperplasia – Pipeline by GL Pharm Tech Corp, H2 2017 30

Benign Prostatic Hyperplasia – Pipeline by Health Ever Bio-Tech Co Ltd, H2 2017 30

Benign Prostatic Hyperplasia – Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017 31

Benign Prostatic Hyperplasia – Pipeline by MEI Pharma Inc, H2 2017 31

Benign Prostatic Hyperplasia – Pipeline by Meiji Seika Pharma Co Ltd, H2 2017 31

Benign Prostatic Hyperplasia – Pipeline by Mezzion Pharma Co Ltd, H2 2017 32

Benign Prostatic Hyperplasia – Pipeline by Nymox Pharmaceutical Corp, H2 2017 32

Benign Prostatic Hyperplasia – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 33

Benign Prostatic Hyperplasia – Pipeline by OPKO Health Inc, H2 2017 33

Benign Prostatic Hyperplasia – Pipeline by SK Chemicals Co Ltd, H2 2017 34

Benign Prostatic Hyperplasia – Pipeline by Sophiris Bio Inc, H2 2017 34

Benign Prostatic Hyperplasia – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 35

Benign Prostatic Hyperplasia – Pipeline by The Female Health Company, H2 2017 35

Benign Prostatic Hyperplasia – Pipeline by XuanZhu Pharma Co Ltd, H2 2017 36

Benign Prostatic Hyperplasia – Pipeline by Yungjin Pharm Co Ltd, H2 2017 36

Benign Prostatic Hyperplasia – Pipeline by Yuyu Pharma Inc, H2 2017 37

Benign Prostatic Hyperplasia – Dormant Projects, H2 2017 98

Benign Prostatic Hyperplasia – Dormant Projects, H2 2017 (Contd..1), H2 2017 99

Benign Prostatic Hyperplasia – Dormant Projects, H2 2017 (Contd..2), H2 2017 100

Benign Prostatic Hyperplasia – Discontinued Products, H2 2017 101

List of Figures

List of Figures

Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Number of Products under Development by Universities/Institutes, H2 2017 14

Number of Products by Top 10 Targets, H2 2017 18

Number of Products by Stage and Top 10 Targets, H2 2017 18

Number of Products by Top 10 Mechanism of Actions, H2 2017 20

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 20

Number of Products by Top 10 Routes of Administration, H2 2017 22

Number of Products by Stage and Top 10 Routes of Administration, H2 2017 22

Number of Products by Molecule Types, H2 2017 24

Number of Products by Stage and Molecule Types, H2 2017 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports